Opus Genetics, Inc. (IRD)
IRD Stock Price Chart
Explore Opus Genetics, Inc. interactive price chart. Choose custom timeframes to analyze IRD price movements and trends.
IRD Company Profile
Discover essential business fundamentals and corporate details for Opus Genetics, Inc. (IRD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Jan 2015
Employees
18.00
Website
https://opusgtx.comCEO
George Magrath
Description
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
IRD Financial Timeline
Browse a chronological timeline of Opus Genetics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.15, while revenue estimate is $2.64m.
Earnings released on 21 May 2026
EPS came in at -$0.19 falling short of the estimated -$0.16 by -18.75%, while revenue for the quarter reached $3.87m , beating expectations by +22.93%.
Earnings released on 12 May 2026
EPS came in at -$0.75 falling short of the estimated -$0.16 by -368.75%, while revenue for the quarter reached $2.16m , missing expectations by -26.33%.
Earnings released on 12 Nov 2025
EPS came in at -$0.12 surpassing the estimated -$0.14 by +14.29%, while revenue for the quarter reached $3.08m , beating expectations by +0.25%.
Earnings released on 13 Aug 2025
EPS came in at -$0.12 surpassing the estimated -$0.25 by +52.00%, while revenue for the quarter reached $2.88m , missing expectations by -6.53%.
Earnings released on 15 May 2025
EPS came in at -$0.32 surpassing the estimated -$0.34 by +5.88%, while revenue for the quarter reached $4.37m , beating expectations by +28.53%.
Earnings released on 31 Mar 2025
EPS came in at -$1.27 falling short of the estimated -$0.34 by -273.53%, while revenue for the quarter reached $4.30m , beating expectations by +26.96%.
Earnings released on 12 Nov 2024
EPS came in at -$0.29 surpassing the estimated -$0.30 by +3.33%, while revenue for the quarter reached $3.87m , missing expectations by -65.18%.
Earnings released on 13 Aug 2024
EPS came in at -$0.30 falling short of the estimated -$0.25 by -20.00%, while revenue for the quarter reached $1.11m , missing expectations by -54.67%.
Earnings released on 10 May 2024
EPS came in at -$0.29 falling short of the estimated -$0.18 by -61.11%, while revenue for the quarter reached $1.71m , missing expectations by -67.96%.
Earnings released on 9 Mar 2024
EPS came in at -$0.22 falling short of the estimated -$0.05 by -315.20%, while revenue for the quarter reached $1.69m , missing expectations by -68.43%.
Earnings released on 13 Nov 2023
EPS came in at $0.25 surpassing the estimated -$0.22 by +211.80%, while revenue for the quarter reached $11.94m , beating expectations by +294.52%.
Earnings released on 30 Jun 2023
EPS came in at -$0.24 falling short of the estimated -$0.23 by -4.73%, while revenue for the quarter reached $3.67m , beating expectations by +51.50%.
Earnings released on 31 Mar 2023
EPS came in at -$0.28 falling short of the estimated -$0.15 by -79.58%, while revenue for the quarter reached $1.75m , missing expectations by -40.74%.
Earnings released on 31 Dec 2022
EPS came in at $1.58 , while revenue for the quarter reached $39.85m .
Earnings released on 30 Sept 2022
EPS came in at -$0.22 surpassing the estimated -$0.28 by +21.62%.
Earnings released on 30 Jun 2022
EPS came in at -$0.25 .
Earnings released on 31 Mar 2022
EPS came in at -$0.35 .
Earnings released on 31 Dec 2021
EPS came in at -$0.35 .
Earnings released on 30 Sept 2021
EPS came in at -$0.25 , while revenue for the quarter reached $489.00k .
IRD Stock Performance
Access detailed IRD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
